Frequency Therapeutics to Present at Upcoming Jefferies and Goldman Sachs Healthcare Investor Conferences

Rhea-AI Summary

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology firm, has announced that CEO David L. Lucchino will present at two upcoming investor conferences. The presentations are scheduled for the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. EDT, and the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 8:00 a.m. EDT. Live webcasts can be accessed on the investors section of Frequency's website, with replays available post-event.

Frequency focuses on developing therapies that activate progenitor cells to treat degenerative diseases, including FX-322 for hearing restoration.

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced that Chief Executive Officer David L. Lucchino will present at two upcoming investor conferences:

• Jefferies Virtual Healthcare Conference on June 2, 2021 at 2:30 p.m. EDT
• Goldman Sachs 42^nd Annual Global Healthcare Conference on June 10, 2021 at 8:00 a.m. EDT

A live webcast of the presentations can be accessed on the investors section of Frequency’s website, investors.frequencytx.com. A replay of the presentations will be posted on the Frequency website following the event.

About Frequency Therapeutics

Frequency Therapeutics is a leader in the development of medicines designed to activate progenitor cells within the body to treat degenerative diseases. The Company’s progenitor cell activation (PCA) approach stimulates progenitor cells to create functional tissue with the aim of developing disease modifying therapies. The Company’s lead product candidate, FX-322, is designed to regenerate auditory hair cells to restore hearing function. FX-322 is being evaluated in multiple ongoing clinical studies in patients with sensorineural hearing loss. The Company also is evaluating additional diseases where its PCA approach could create functional tissue, including in a pre-clinical program in multiple sclerosis.

Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, Massachusetts Institute of Technology, The Scripps Research Institute and Cambridge Enterprises Limited. For more information, visit www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210525005105/en/

FAQ

What is the schedule for Frequency Therapeutics' CEO presentations?

David L. Lucchino will present at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 2:30 p.m. EDT and at the Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 8:00 a.m. EDT.

Where can I watch the Frequency Therapeutics presentations?

The presentations can be viewed live on the investors section of Frequency Therapeutics’ website, with replays available after the events.

What is Frequency Therapeutics focused on?

Frequency Therapeutics focuses on developing medicines that activate progenitor cells to treat degenerative diseases. Their lead product, FX-322, aims to regenerate auditory hair cells for hearing restoration.

What is FX-322 and its purpose?

FX-322 is Frequency Therapeutics’ lead product candidate designed to regenerate auditory hair cells to restore hearing function, currently under clinical evaluation for sensorineural hearing loss.

What collaborations does Frequency Therapeutics have?

Frequency Therapeutics has collaborations with Astellas Pharma for FX-322 and partnerships with academic and nonprofit organizations, including MIT and The Scripps Research Institute.